# STOCKHOLM 1.0
#=GF ID   CompInhib_SCIN
#=GF AC   PF11546.12
#=GF DE   Staphylococcal complement inhibitor SCIN 
#=GF AU   Pollington J;0000-0002-8158-8998
#=GF SE   pdb_2qff
#=GF GA   23.00 23.00;
#=GF TC   23.60 24.80;
#=GF NC   20.60 22.80;
#=GF BM   hmmbuild HMM.ann SEED.ann
#=GF SM   hmmsearch -E 1000 -Z 75585367 --cpu 4 HMM pfamseq
#=GF TP   Family
#=GF RN   [1]
#=GF RM   17709514
#=GF RT   Staphylococcal complement inhibitor: structure and active sites. 
#=GF RA   Rooijakkers SH, Milder FJ, Bardoel BW, Ruyken M, van Strijp JA,
#=GF RA   Gros P; 
#=GF RL   J Immunol. 2007;179:2989-2998.
#=GF DR   INTERPRO; IPR021612;
#=GF DR   SO; 0100021; polypeptide_conserved_region;
#=GF CC   SCIN is released by Staphylococcus aureus to counteract the host
#=GF CC   immune defense. The protein binds to and inhibits C3 convertases
#=GF CC   on the bacterial surface, reducing phagocytosis and blocking
#=GF CC   downstream effector functions by C3b deposition on its surface
#=GF CC   [1]. An 18 residue stretch 31-48 is crucial for SCIN activity
#=GF CC   [1].
#=GF SQ   3
#=GS SCIN_STAA8/1-114    AC Q2FWV6.1
#=GS Q2G1D4_STAA8/5-111  AC Q2G1D4.1
#=GS Q2FZB7_STAA8/1-116  AC Q2FZB7.1
SCIN_STAA8/1-114               MKIRKSILAGTLAIVLASPLVTNLDKNEAQASTSLP..TSNEYQNEKLANELKSLLDELNVNELATGSLNTYYKRTIKISGLKAMYALKSKDFKKMSEAKYQLQKIYNEIDEALKS
Q2G1D4_STAA8/5-111             MKIKTYLVAGIKAALLDTTGIKLASKSET.........TSHTYQHQALVDQLHELIANTDLNKLSYLNLDAFQKRDILAAHYIAKSAIRTKNLDQMTKAKQRLESIYNSISNPLHS
Q2FZB7_STAA8/1-116             MKFKKYILTGTLALLLSSTGIATIEGNKADASSLDKYLTESQFHDKRIAEELRTLLNKSNVYALAAGSLNPYYKRTIMMNEYRAKAALKKNDFVSMADAKVALEKIYKEIDEIINR
#=GC seq_cons                  MKIKKYILAGTLAlLLuSTGIssl-KNEApASo.....TSspYQcc+LA-EL+oLLscoNVNcLAsGSLNsYYKRTIhhucY+AKuALKoKDFcpMo-AKhpLEKIYNEIDEsL+S
